Journal article
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of highly or moderately emetogenic chemotherapy (HEC, MEC).
Abstract
210
Authors
Rapoport BL; Schwartzberg LS; Chasen MR; Powers D; Arora S; Navari RM; Schnadig ID
Journal
Journal of Clinical Oncology, Vol. 33, No. 29_suppl, pp. 210–210
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
October 10, 2015
DOI
10.1200/jco.2015.33.29_suppl.210
ISSN
0732-183X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Administration, OralAdultAgedAged, 80 and overAntiemeticsAntineoplastic Combined Chemotherapy ProtocolsClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicDexamethasoneDouble-Blind MethodDrug Therapy, CombinationFemaleGranisetronHumansMaleMiddle AgedNauseaNeoplasmsNeurokinin-1 Receptor AntagonistsOndansetronRandomized Controlled Trials as TopicRetreatmentSerotonin 5-HT3 Receptor AntagonistsSpiro CompoundsTreatment OutcomeVomitingYoung Adult